DRAI yields 1.59% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, DRAI + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DRAI + JNJ for your $10,000?
DRAI aims for long-term capital appreciation by holding 10-20 ETF positions across a variety of asset classes including US equities, gold, fixed-income securities, and more. The fund uses an AI model trained on historical pricing data to predict short-term market trends and volatility, which influences 70% of its asset selections. This is complemented by a macroeconomic model analyzing data like unemployment insurance applications and interest rate spreads to inform long-term outlooks. Combined, they make up the funds proprietary AI system called the Draco Model. In bearish markets, DRAI leans towards US treasury bonds and inverse ETFs, in bullish markets, it favors US equities and leveraged ETFs. The fund continually rebalances based on daily market conditions and has mechanisms to provide downside protection but may experience increased volatility due to leveraged investments. The Funds sub-adviser has the discretion to override the AI model in extreme circumstances.
Full DRAI Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.